Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | India | Ireland | Italy | New Zealand | Pakistan | Peru | Russia | Taiwan | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Region Midtjylland
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, Norway
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Head and Neck Cancer|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DAHANCA 30 | P3 |
Unknown Status |
Squamous Cell Carcinoma|Head and Neck Cancer |
2029-12-01 |